A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer

Clinical Breast Cancer

Volumn 9, Issue 4, 2009, Pages 247-252

  Yardley, Denise A ^a,b   Burris III, Howard A ^a,b   Spigel, David R ^a,b   Clark, Bobby L ^a   Vazquez, Elizabeth ^a   Shipley, Dianna ^a,b   Barton, John ^a,b   Thompson, Dana ^a,b   Montes, Ignacio ^c   Greco, F Anthony ^a,b   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Tennessee Oncology   (United States)

^c Consultants in Blood Disorder and Cancer ^*  (United States)

Author keywords

Anthracycline; Dose modification; Myelosuppression; Single agent treatment; Taxane

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN;

ADJUVANT CHEMOTHERAPY; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; TUMOR GROWTH;

EID: 73349139189     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.042     Document Type: Article

References (10)

1. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003; 21:588-592
2. Alba E, Martin M, Ramus M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22:2587-2593
3. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980-1986
4. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22:3893-3901
5. Wigler N, Inbar M, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) versus doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:45a (Abstract 177).
6. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-3505
7. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219
8. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112:1455-1461
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer institute of Canada. J Natl Cancer Inst 2000; 92:205-216
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481